drug

taliglucerase alfa

Marketedupdated 3mo ago

by $PFE PFIZER INC

Approved

community read0 votes

🐶 often sniffed alongside

top 3

Enzyme drug with a maximum clinical stage of Approval (across all indications), with an approval for gaucher disease and metabolic disease and 1 investigational indication.

all catalysts(18)

approval · 18

ELELYSO (TALIGLUCERASE ALFA) — FDA approval

ELELYSO (TALIGLUCERASE ALFA) — FDA approval

ELELYSO (TALIGLUCERASE ALFA) — FDA approval

ELELYSO (TALIGLUCERASE ALFA) — FDA approval

ELELYSO (TALIGLUCERASE ALFA) — FDA approval

ELELYSO (TALIGLUCERASE ALFA) — FDA approval

ELELYSO (TALIGLUCERASE ALFA) — FDA approval

ELELYSO (TALIGLUCERASE ALFA) — FDA approval

ELELYSO (TALIGLUCERASE ALFA) — FDA approval

ELELYSO (TALIGLUCERASE ALFA) — FDA approval

ELELYSO (TALIGLUCERASE ALFA) — FDA approval

ELELYSO (TALIGLUCERASE ALFA) — FDA approval

ELELYSO (TALIGLUCERASE ALFA) — FDA approval

ELELYSO (TALIGLUCERASE ALFA) — FDA approval

ELELYSO (TALIGLUCERASE ALFA) — FDA approval

ELELYSO (TALIGLUCERASE ALFA) — FDA approval

ELELYSO (TALIGLUCERASE ALFA) — FDA approval

ELELYSO (TALIGLUCERASE ALFA) — FDA approval

taliglucerase alfa

→

view all 18 catalysts →

Trials studying taliglucerase alfa

phase4A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Diseasecompletedn=14

News(0)

no news has mentioned this drug yet

brand

Elelyso

generic

taliglucerase alfa

MOA

12.1 Mechanism of Action Gaucher disease is an autosomal recessive disorder caused by mutations in the human glucocerebrosidase gene, which results in a reduced activity of the lysosomal enzyme glucocerebrosidase. Glucocerebrosidase catalyzes the conversion of the sphingolipid glucocerebroside into glucose and ceramide. The enzymatic deficiency results in accumulation of substrate glucocerebroside primarily in the lysosomal compartment of macrophages, giving rise to foam cells or "Gaucher cells," which accumulate in the liver, spleen and bone marrow. ELELYSO, an enzyme replacement therapy, is a recombinant analog of human lysosomal glucocerebrosidase that catalyzes the hydrolysis of glucocerebroside to glucose and ceramide, reducing the amount of accumulated glucocerebroside. ELELYSO uptake into cellular lysosomes is mediated by binding of ELELYSO mannose oligosaccharide chains to specific mannose receptors on the cell surface leading to internalization and subsequent transport to the lysosomes.

indication

Gaucher Disease Type I

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

taliglucerase alfa

🐶 often sniffed alongside

all catalysts(18)

Trials studying taliglucerase alfa

News(0)

Report a data issue

comments(0)

taliglucerase alfa

🐶 often sniffed alongside

all catalysts(18)

Trials studying taliglucerase alfa

News(0)

Report a data issue

comments(0)